TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
2.970
+0.040 (1.37%)
At close: Dec 20, 2024, 4:00 PM
3.040
+0.070 (2.36%)
After-hours: Dec 20, 2024, 4:37 PM EST

TScan Therapeutics Revenue

TScan Therapeutics had revenue of $1.05M in the quarter ending September 30, 2024, a decrease of -73.01%. This brings the company's revenue in the last twelve months to $9.36M, down -44.71% year-over-year. In the year 2023, TScan Therapeutics had annual revenue of $21.05M with 55.52% growth.

Revenue (ttm)
$9.36M
Revenue Growth
-44.71%
P/S Ratio
16.93
Revenue / Employee
$60,792
Employees
154
Market Cap
167.82M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202321.05M7.51M55.52%
Dec 31, 202213.54M3.39M33.47%
Dec 31, 202110.14M9.06M834.65%
Dec 31, 20201.09M--
Dec 31, 2019---
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Nektar Therapeutics 93.14M
Fennec Pharmaceuticals 49.35M
BrainsWay 38.63M
scPharmaceuticals 30.28M
Elutia 24.78M
Caribou Biosciences 11.48M
Lyell Immunopharma 63.00K
Revenue Rankings